How IMM-101 works

IMM-101 is an investigational medicinal product. It is intended to be used in combination with other standard-of-care anti-cancer treatments, such as immune checkpoint inhibitors and chemotherapy, to improve the overall outcome for patients without substantially compromising on patient’s safety and quality of life. Early phase clinical studies have produced encouraging safety results and increases in survival in patients with metastatic pancreatic cancer and advanced (unresectable) melanoma.


IMM-101 contains a naturally occurring, heat-killed whole cell Mycobacterium called M. obuense. This bacterium is part of the Immodulon family of immunomodulators derived from carefully selected bacteria belonging to the Actinomycetales order of bacteria, which in their wider application can potentially be used as immunotherapy treatments in cancer or in certain diseases associated with chronic inflammation and as a vaccine for tuberculosis.

IMM-101 Mechanism of Action (MoA)

IMM-101’s main MoA is that it activates early stage dendritic cells and skews their maturation into dendritic cells that induce Type I immune responses ultimately resulting in the generation of cytotoxic T cells, which are essential for killing cancer cells. In addition, IMM-101 treatment results in the activation and multiplication of various other immune cells involved in controlling cancer.

IMM-101 activates all of the most relevant anti-cancer immune cells

The immune system must be in good working order to kill tumour cells but is often suppressed in patients with cancer
IMM-101 improves the immune system and activates all known immune cells that have been shown to be of high importance for attacking cancer
Immune system and its cells activated by IMM-101

IMM-101 main MoA: Activation of Dendritic Cells and Cytotoxic T Cell Generation

Critically, IMM-101 activates immature dendritic cells (DCs) into Type I DCs (cDC1), which ultimately leads to the activation of CD8+ immune cells to become cancer-specific cytotoxic T lymphocytes (CTLs)
These CTLs multiply, recognize and bind to cancer cells and subsequently release aggressive cytotoxins which kill the cancer cells